Navigating UnitedHealthcare Spravato Prior Authorization

Understanding Spravato for UnitedHealthcare Members

Spravato, an esketamine nasal spray, is indicated for treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Given its specialized nature and administration requirements, UnitedHealthcare typically subjects Spravato to stringent prior authorization requirements to ensure medical necessity and appropriate use according to their coverage policies.

UnitedHealthcare's Prior Authorization Channels for Spravato

UnitedHealthcare leverages distinct channels for prior authorization submissions, depending on whether Spravato is covered under the medical or pharmacy benefit. Specialty drugs like Spravato often fall under the purview of OptumRx, UnitedHealth Group's PBM, or the medical benefit, necessitating careful verification of the member's specific plan and benefit design.

Key Submission Pathways for Spravato PA with UHC

• **Pharmacy Benefit:** For Spravato covered under the pharmacy benefit, submissions typically route through OptumRx's provider PA system or through ePA partners like CoverMyMeds and Surescripts for prescriber-initiated workflows.
• **Medical Benefit:** If Spravato falls under the medical benefit, prior authorization requests are generally processed via the UnitedHealthcare Provider Portal at UHCprovider.com, which supports procedure-specific PA initiation and document upload.
• **X12 278 Transactions:** UnitedHealthcare supports X12 278 transactions via clearinghouses for medical benefit prior authorizations, offering an electronic pathway for eligible procedures.
• **Specialty Drug Program:** The specific medical/pharmacy benefit split for specialty injectables and infusions like Spravato is therapeutic-class specific and may involve Optum Specialty Pharmacy. Verification of the current Specialty Pharmacy Drug Program list is essential.

UnitedHealthcare Medical Necessity Criteria for Spravato

UnitedHealthcare publishes its medical necessity criteria and coverage rules through its public Medical Policy Library. For Spravato, policies will outline specific clinical indications, dosing, duration limits, and step therapy requirements. It is crucial to reference the specific policy number and effective date to ensure compliance with the most current guidelines when preparing a prior authorization request.

Common Denial Reasons and Appeal Pathways for Spravato with UHC

Denials for Spravato prior authorizations from UnitedHealthcare often stem from insufficient clinical documentation, failure to meet medical necessity criteria, or non-adherence to step therapy protocols. UnitedHealthcare returns denials via X12 277/835 transactions for electronic submissions or portal status updates. The appeal pathway, detailed in UHC's provider administrative guides, varies by line of business (commercial, Medicare Advantage, Medicaid) and includes options for peer-to-peer reviews for clinical denials.

Navigating Turnaround Times and Electronic PA Initiatives

UnitedHealthcare's prior authorization turnaround times are influenced by state-mandated minimums, NCQA Utilization Management accreditation standards, and payer-published service-level targets. For Medicare Advantage and UnitedHealthcare Community Plan (Medicaid managed care) lines, CMS-0057-F mandates phased compliance for electronic PA APIs and decision timeframes (72 hours for standard, 24 hours for expedited), which will impact future electronic submission processes. UnitedHealthcare is also a participant in the HL7 Da Vinci Project, exploring advanced electronic PA solutions.